IPO

Led by a controversial figure, AlphaTON Capital pitches a bold Web3 vision in Abu Dhabi, but its grand ambitions clash with stark financial realities.

Law firm Gunderson Dettmer's major partner expansion signals confidence not in the whole market, but in the AI-driven, high-value core of the venture economy.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

Amidst a nuclear renaissance, Global Uranium’s detailed mapping in Wyoming de-risks a key project, setting the stage for a critical 2026 drill program.

JFB Construction's CEO just invested $100k of his own money in company stock. We dive into the projects and market trends fueling this bold move.

Spectral Capital projects massive growth via acquisitions and quantum tech, but its ambitious NASDAQ plan faces significant financial and execution hurdles.

The space tourism pioneer is restructuring its debt, buying precious time for its next-gen fleet but at a steep cost for shareholders and future finances.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

A $900k stock grant to a new exec reveals more than a salary. It's a look into biotech's talent war and the financial tools used to secure human assets.

Insiders at the newly independent Magnum Ice Cream Company show major confidence with multi-million-euro share buys following its spin-off from Unilever.

A landmark deal for two Airbus A321neos signals more than fleet expansion; it's a strategic play to turn Tashkent into the next major East-West air hub.

A routine regulatory filing reveals Sintana Energy's major M&A play. We decode the signals, the Challenger deal, and what it means for its oil future.

Netcapital's huge 1M share grant to its new CEO is a high-stakes play. We decode the strategy, the risk, and the ambitious revenue targets.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

Broadway star Morgan Dudley returns to the tech platform that discovered her. Can her insider role help Stargaze win the high-stakes talent-tech race?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.